The Active Pharmaceutical Ingredient (API) forms the most vital part of any finished dosage product. The overall API market was valued at USD 101.08 billion in 2011, and is expected to grow at a CAGR of 7.9% from 2011 to 2016.
Global generic markets are witnessing a period of unprecedented growth as blockbuster drug patents expire and the need for managing healthcare costs drives generic substitution globally. Strength in API is an integral part of capitalizing on this opportunity. As players globally come under pressure owing to weak regulatory compliance, quality or inefficient cost-base issues, India remains one of most favored API destinations globally.
Lupin's strengths and cost leadership in APIs have been a critical part of Lupin's emergence as a global generic and branded formulation powerhouse. Our API strengths have not only enabled forging of better synergies between our diverse formulation businesses but have also helped create new opportunities for the future. Today, Lupin is one of the most vertically integrated global generic majors; a market leader on both fronts of the pharmaceutical business, API and Formulations.
In FY 2012, the company's API business generated revenues of ` 8,491 million. The Company remains a global leader in therapeutic areas such as Cephalosporins, Cardiovasculars and the anti-TB space. The Company has been a global market leader in products such as Rifampicin, Pyrazinamide and Ethambutol, as well as in Cephalosporins such as Cephalexin, Cefaclor and their Intermediates for over a decade. The Company remains a strategic supplier of anti-TB products to the Global Drug Facility (GDF), thus maintaining its premier position in Tuberculosis treatment.